Multiplexed CRISPR/Cas9 Editing of Tumor Suppressor Genes Recapitulates Molecular and Morphological Features of High-Risk Endometrial Cancer
Maria Vidal-Sabanés, Raúl NavaridasiD, Núria BonifaciiD, Ada Gay-Rua, Damià Ortega-Peinado, Joaquim EgeaiD, Mario EncinasiD, Xavier Matías‐GuiuiD, David Llobet-Navas, Xavier DolcetiD
Abstract
High-risk endometrial cancers (EC), such as uterine carcinosarcomas (UCS) and serous endometrial intraepithelial carcinoma (SEIC), are characterized by frequent mutations in tumor suppressor genes (TSGs) and poor clinical outcomes. Traditional genetically engineered mouse models are limited in flexibility and scalability to study the cooperative effects of multiple TSG alterations. Here, we use a multiplexed CRISPR/Cas9-based approach to simultaneously edit the top ten TSGs commonly mutated in high-risk EC directly in the mouse endometrium via intrauterine electroporation. Using rolling circle amplification (RCA) and next-generation sequencing, we demonstrate that this method induces targeted gene editing in a mosaic manner, mimicking tumor heterogeneity. We demonstrate that this approach generates histologically and molecularly faithful models of SEIC and UCS. Importantly, some edited tissues remained histologically normal, emphasizing the complex multistep nature of endometrial tumorigenesis. These CRISPR/Cas9-generated murine models serve as robust platforms to dissect the molecular underpinnings of high-risk endometrial cancer and to accelerate preclinical evaluation of novel therapeutic strategies.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transient and DNA-free in vivo CRISPR/Cas9 genome edition for flexible modelling of endometrial carcinogenesis
X. Dolcet·bioRxiv·Jun 17, 2022
- In vivo intra-uterine delivery of TAT-fused Cre recombinase and CRISPR/Cas9 editing unveil histopathology of Pten/p53-deficient endometrial cancers.
R. Navaridas, M. Vidal-Sabanes, … X. Dolcet·bioRxiv·Jun 8, 2023
- Modeling High-grade serous ovarian carcinoma using a combination of in vivo electroporation and CRISPR/Cas9 mediated genome editing
K. Teng, M. J. Ford, … Y. Yamanaka·bioRxiv·Mar 29, 2021
- Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer
Z. Blanchard, J. M. Vahrenkamp, … J. Gertz·bioRxiv·Jul 3, 2019
- Enhancer plasticity in endometrial tumorigenesis demarcates non-coding somatic mutations and 3D-genome alterations boosting the oncogenic driver ESR1
S. Gregoricchio, A. Kojic, … W. Zwart·bioRxiv·Jul 25, 2023
- Allele-specific gene regulation, phenotypes, and therapeutic vulnerabilities in estrogen receptor alpha mutant endometrial cancer
Z. Blanchard, C. M. Rush, … J. Gertz·bioRxiv·Jun 13, 2022